Status:
COMPLETED
A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides
Lead Sponsor:
Pfizer
Conditions:
Hypertriglyceridemia
Hyperlipoproteinemia Type IV
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To assess the safety and efficacy of the fixed combination torcetrapib/atorvastatin in subjects with Fredrickson Typ...
Detailed Description
For additional information please call: 1-800-718-1021
Eligibility Criteria
Inclusion
- Diagnosis of Fredrickson Type IV Hypertriglyceridemia
Exclusion
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00134498
Start Date
February 1 2005
End Date
November 1 2006
Last Update
November 16 2007
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Anaheim, California, United States
2
Pfizer Investigational Site
Huntington Beach, California, United States
3
Pfizer Investigational Site
Los Angeles, California, United States
4
Pfizer Investigational Site
Orange, California, United States